Eli Lilly
LLY
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 7 hours ago • LLY
Should You Dump Eli Lilly's Shares After This Setback?
Investors Business Daily • 10 hours ago • LLY
Google, Nvidia, Lilly Lead 5 Stocks Near Buy Points
PRNewsWire • 1 day ago • LLY
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
Investors Business Daily • 1 day ago • LLY
Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues
Zacks Investment Research • 2 days ago • LLY
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.